ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2023 Earnings Call Transcript

Jennifer Bath: Yes, sure. Thank you. All right. So now first of all, I wanted to start by just talking a little bit about the fact that we have accomplished, a great deal in developing, integrating these new technologies to drive our commercial potential. We’ve also been successful in recruiting and assembling a world-class team which continues to execute on our stated objectives to achieve new heights in terms of our commercial goals. All of this was accomplished also while delivering on our partnerships and signing our first extended revenue potential deal which is the in silico licensing agreement with BriaCell. We are confident and we remain confident in our capacity to continue acquiring new in silico partners and programs this year, as well as our potential to realize revenue through comparable agreement structures through our Talem Therapeutics subsidiary.

Prior to closing, I would like to recognize and thank our team for their unwavering commitment and remarkable efforts so far this year. And as you can tell, we are very enthusiastic about the future, and we look forward to communicating with all of you and even meeting some of you next month at JPMorgan. And we appreciate your attention and again, we look forward to speaking with all of you soon.

Operator: Thank you all for joining today’s call. You may now disconnect.